RYCFX Mutual Fund

RYCFX Mutual Fund

NAV$52.05
See how much of RYCFX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Jul 31, 2026

Net Assets
$415,566.92
Expense Ratio
2.38%
Dividend Yield (Current)
-
Holdings
69
Inception Date
Mar 30, 2001
Fund Family
Rydex Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO

Performance

YTD+25.35%
1 Year+44.65%
3 Year+33.94%
5 Year+13.12%
10 Year+12.78%

Asset Allocation

Stocks: 99.37%
Other: 0.63%
See how much of RYCFX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
ABBVAbbvie Inc.8.47%
AMGNAmgen Inc.5.58%
GILDGilead Sciences4.81%
VRTXNvaesrtex Pharmaceuticals Inc4.31%
REGNRegeneron Pharmaceuticals, Inc.3.73%
Top 10 Concentration: 38.68%Report Date: Jul 31, 2026
Download all 69 holdings for RYCFX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Latest Distribution
$15.77
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

RYCFX Mutual Fund Overview

RYCFX Mutual Fund (Rydex Biotechnology Fund Class C) is managed by Rydex Funds with $415,566.92 in net assets. RYCFX expense ratio is 2.38%, holding 69 positions across sectors including Health Care. Inception date: 2001-03-30.

RYCFX performance shows a YTD return of 25.35%. The 1-year return is 44.65% and the 5-year return is 13.12%.

RYCFX top holdings include Abbvie Inc. (8.5%), Amgen Inc. (5.6%), Gilead Sciences (4.8%), Nvaesrtex Pharmaceuticals Inc (4.3%), Regeneron Pharmaceuticals, Inc. (3.7%). Go to all RYCFX holdings, RYCFX sectors, or RYCFX dividends.

RYCFX can be compared against other funds. Use RYCFX overlap to find shared positions, or RYCFX vs another fund for a side-by-side view. RYCFX alternatives are available via the screener, along with tax-loss harvesting opportunities.